Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Financière de Tubize S.A. (TUB.BR)
Brussels, BE
Financière de Tubize SA, headquartered in Brussels, Belgium, operates as a global biopharmaceutical firm, primarily through its investment in UCB. The company is dedicated to discovering and advancing innovative medicines and solutions focused on neurological and immunological disorders. Its current commercial offerings include Cimzia, an established treatment for a range of inflammatory conditions such as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis. For partial-onset seizures in epilepsy, it provides Briviact, Vimpat, and Keppra, alongside Nayzilam, a nasal spray. Neupro addresses Parkinson's disease and restless legs syndrome. Additionally, the portfolio features Evenity, an injectable therapy for osteoporosis, and Bimzelx, used to manage moderate to severe plaque psoriasis. The company's development pipeline highlights several promising candidates: Staccato, aimed at stereotypical prolonged seizures; Bepranemab for Alzheimer's disease; and UCB0599 for Parkinson's disease. Other therapies under investigation include bimekizumab, which targets psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; rozanolixizumab, for conditions like myasthenia gravis, immune thrombocytopenia, myelin oligodendrocyte glycoprotein antibody disease, and autoimmune encephalitis; and dapirolizumab pegol, intended for systemic lupus erythematosus.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +5.84% | +7.05% | +14.87% | -0.75% | +7.05% | +7.56% | +77.29% | +213.53% | +188.95% | +307.03% | +11,253.54% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 0 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%-100.0% Q4'25: -100.0% (vs Q4'23)
-
EPS growth Biotechnology: +29.7%+3.5% Q4'25: +19.7% (vs Q4'23)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%+5.1% ★ Q4'25: -0.4% (vs Q4'23)
-
Share dilution Biotechnology: -3.4%+0.0% ★ Q4'25: +0.0% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.00× ★ Q4'25: 0.00× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2011 actual |
|---|---|
| Revenue |
—
est: 66.08M (-100.0%)
|
| EBITDA |
-14.69M
est: 26.43M (-155.6%)
|
| EBIT |
-14.69M
est: 13.22M (-211.1%)
|
| Net Income |
64.69M
est: 52.60M (+23.0%)
|
| SGA |
—
est: 121.95M (-100.0%)
|
| EPS |
1.45
est: 1.18 (+22.7%)
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C+ | 2/5 | 2/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-28 | C+ | 2/5 | 2/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-27 | C+ | 2/5 | 2/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-26 | C+ | 2/5 | 2/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-25 | C+ | 2/5 | 2/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-22 | C+ | 2/5 | 2/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-21 | C+ | 2/5 | 2/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-20 | C+ | 2/5 | 2/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-19 | C+ | 2/5 | 2/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-18 | C+ | 2/5 | 2/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-15 | C+ | 2/5 | 2/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-14 | C+ | 2/5 | 2/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-13 | C+ | 2/5 | 2/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-12 | C+ | 2/5 | 2/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-11 | C+ | 2/5 | 2/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-08 | C+ | 2/5 | 2/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-07 | C+ | 2/5 | 2/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-06 | C+ | 2/5 | 2/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-05 | C+ | 2/5 | 2/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-04 | C+ | 2/5 | 2/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-30 | C+ | 2/5 | 2/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-29 | C+ | 2/5 | 2/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-28 | C+ | 2/5 | 2/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-27 | C+ | 2/5 | 2/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-24 | B- | 2/5 | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-23 | B- | 2/5 | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-22 | B- | 2/5 | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-21 | B- | 2/5 | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-20 | B- | 2/5 | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-17 | B- | 2/5 | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-16 | B- | 2/5 | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-15 | B- | 2/5 | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Eric Nys | Managing Director | 239.5K | male |
| Anne Sophie Pijcke | General Manager | 37.0K | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for TUB.BR
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
